Advertisement

Breast Cancer Research and Treatment

, Volume 167, Issue 2, pp 605–606 | Cite as

Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer

  • Muhammad Asaduzzaman
  • Stephanie Constantinou
  • Haoxiang Min
  • John Gallon
  • Meng-Lay Lin
  • Poonam Singh
  • Selina Raguz
  • Simak Ali
  • Sami Shousha
  • R. Charles Coombes
  • Eric W.-F. Lam
  • Yunhui Hu
  • Ernesto Yagüe
Correction
  • 407 Downloads

Correction to: Breast Cancer Res Treat (2017) 163:461–474  https://doi.org/10.1007/s10549-017-4202-z

In the original publication, Fig. 1 depicting the blot for EP300 in CAL51 cells (Fig. 1c) was unintentionally duplicated with that from MDA-MB-231 cells (Fig. 1d). The new figure given in this erratum depicts the correct EP300 blot in Fig. 1c.
Fig. 1

Experimental modulation of EP300 in cellular models. Expression of EP300 and E-cadherin was determined by immunoblot analyses. a EP300 was downregulated in breast cancer luminal MCF-7 cells by lentiviral expression of two different EP300 hairpins (MCF7-shEP300-1 and MCF7-shEP300-2). Cells expressing the empty pGIPZ vector (MCF7-shev) were used as control. b A genetic knock-out of EP300 (HCT-KOEP300) is available in colon carcinoma HCT116 cells. This cell line is hemizygous for the EP300 locus and generates a C-terminus truncated EP300 protein [10]—note its lower molecular mass (tEP300, truncated EP300). Paclitaxel-resistant derivatives are indicated with the -TX name extension. c, d EP300 was upregulated in breast cancer basal-like CAL51 and MDA-MB-231 cells with an EP300 expression cassette in pcDNA3.1 (CAL-EP300 and MDA-EP300). In both cases, cells transfected with pcDNA3.1 were used as controls (CAL-ev and MDA-ev). Lamin B was used as a loading control. Representative pictures of three replicates are shown. Immunoblots were quantified and data are shown in the histograms as average ± SD of three blots. All statistical comparisons (*P < 0.05) versus control cells

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Muhammad Asaduzzaman
    • 1
    • 5
  • Stephanie Constantinou
    • 1
    • 6
  • Haoxiang Min
    • 1
  • John Gallon
    • 1
  • Meng-Lay Lin
    • 1
  • Poonam Singh
    • 2
  • Selina Raguz
    • 3
  • Simak Ali
    • 1
  • Sami Shousha
    • 2
  • R. Charles Coombes
    • 1
  • Eric W.-F. Lam
    • 1
  • Yunhui Hu
    • 4
  • Ernesto Yagüe
    • 1
  1. 1.Division of CancerImperial College Faculty of MedicineLondonUK
  2. 2.Centre for Pathology, Department of Medicine, Imperial College Faculty of MedicineCharing Cross HospitalLondonUK
  3. 3.Division of Clinical SciencesImperial College Faculty of MedicineLondonUK
  4. 4.The 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, National Clinical Research Center of CancerTianjin Medical University Cancer Institute and HospitalTianjinPeople’s Republic of China
  5. 5.Department of Clinical Pharmacy and PharmacologyUniversity of DhakaDhakaBangladesh
  6. 6.MRC Cancer UnitHutchison/MRC Research CentreCambridgeUK

Personalised recommendations